Publication:
Treatment patterns and clinical outcomes in patients with relapsed/refractory Hodgkin lymphoma receiving stem cell transplantation outside Europe and North America: results from the B-HOLISTIC study

dc.contributor.coauthorAl-Mansour, M.
dc.contributor.coauthorZerga, M.
dc.contributor.coauthorBrittain, D.
dc.contributor.coauthorYeh, S. -P.
dc.contributor.coauthorTumyan, G.
dc.contributor.coauthorSong, Y.
dc.contributor.coauthorKarduss, A.
dc.contributor.coauthorRivas-Vera, S.
dc.contributor.coauthorHertzberg, M.
dc.contributor.coauthorTye, L. S.
dc.contributor.coauthorKwong, Y. L.
dc.contributor.coauthorHuang, Z.
dc.contributor.coauthorWu, K. -W.
dc.contributor.coauthorKim, T. M.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorFerhanoğlu, Ahmet Burhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T11:49:22Z
dc.date.issued2022
dc.description.abstractInformation on Hodgkin lymphoma (HL) is mostly limited to Europe and North America. Thisreal-world, retrospective study assessed treatment pathways and clinical outcomes in adults withstage IIB–IV classical HL receiving frontline treatment (n¼1598) or relapsed/refractory HL (RRHL,n¼426) in regions outside Europe and North America between January 2010 and December2013. The primary endpoint was progression-free survival (PFS) in the RRHL group. Amongpatients with RRHL, 89.0% received salvage chemotherapy; most common regimen was etopo-side, methylprednisolone, cytarabine, cisplatin (ESHAP; 26.3%). Median PFS in the RRHL groupwas 13.2months (95% confidence interval [CI]: 9.9–20.2) and was longer in patients withvs.with-out stem cell transplantation (SCT; 20.6vs.7.5 months;p¼0.0071). This large-scale study identi-fied a lower PFS for RRHL in the rest of the world compared with Europe and North America,highlighting the need for novel targeted therapies and SCT earlier in the treatment continuum.
dc.description.fulltextYES
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue14
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis study was funded by Takeda Pharmaceuticals International AG - Singapore Branch.
dc.description.versionPublisher version
dc.description.volume63
dc.identifier.doi10.1080/10428194.2022.2126281
dc.identifier.eissn1476-5365
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR04098
dc.identifier.issn0268-3369
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85139568671
dc.identifier.urihttps://hdl.handle.net/20.500.14288/642
dc.identifier.wos864768800001
dc.keywordsHodgkin lymphoma
dc.keywordsRelapsed/refractory
dc.keywordsTreat-ment outcome
dc.keywordsDevelopingcountry
dc.keywordsReal-world evidence
dc.language.isoeng
dc.publisherTaylor _ Francis
dc.relation.grantnoNA
dc.relation.ispartofLeukemia and Lymphoma
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10983
dc.subjectOncology
dc.subjectHematology
dc.titleTreatment patterns and clinical outcomes in patients with relapsed/refractory Hodgkin lymphoma receiving stem cell transplantation outside Europe and North America: results from the B-HOLISTIC study
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorFerhanoğlu, Ahmet Burhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10983.pdf
Size:
2.1 MB
Format:
Adobe Portable Document Format